Mar 08, 2022 / 08:25PM GMT
Elliot Henry Wilbur - Raymond James & Associates, Inc., Research Division - Senior Research Analyst
Good afternoon. Welcome to the Viatris presentation at Raymond James' 43rd Annual Institutional Investor Conference. Viatris is an emerging global pharmaceutical leadership name, formed via the combination of Pfizer's legacy Upjohn business and Mylan's global generics and specialty branded products business.
From the company here today, CEO, Michael Goettler; CFO; Sanjeev Narula. Michael?
Michael Goettler - Viatris Inc. - CEO & Executive Director
Yes. Thank you, Elliot, and thanks for inviting us. Just wanted for those that are not that familiar with the name, summarize a little bit. We had -- about a week ago, we had an investor event, and I just want to summarize what we announced.
We announced, number one, a deal with Biocon Biologics on combining our biosimilar business in return for up to $3.335 billion, $2 billion upfront and then some participation in 12.9% stake in the future company. That's a deal that is, number one, creating a
Viatris Inc at Raymond James Institutional Investors Conference Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers